Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety, Tolerability and Antiviral Activity of GS-9688 in Viremic Adult Subjects With Chronic Hepatitis B Who Are Not Currently on Treatment

Next Previous
Search
Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety, Tolerability and Antiviral Activity of GS-9688 in Viremic Adult Subjects With Chronic Hepatitis B Who Are Not Currently on Treatment

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 22 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Selgantolimod (Primary) ; Tenofovir alafenamide
  • Indications Hepatitis B
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Gilead Sciences

Most Recent Events

  • 26 Oct 2022 Results of safety and efficacy of 24 weeks of SLGN treatment in viremic CHB patients, presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2022
  • 26 Jun 2021 Results of week 48 data from the safety and efficacy of 24 weeks of SLGN treatment in viremic chronic hepatitis B patients, presented at The International Liver Congress 2021.
  • 10 Dec 2020 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top